Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Key research findings include: Average 24.2% body weight reduction in Phase 2 at the highest dose cohort over 48 weeks Significant reductions in waist circumference, triglycerides, and fasting glucose Weekly subcutaneous injection (half-life approximately 6 days) Most common adverse events: nausea, vomiting, diarrhea (typical of GLP-1 class) Requires cold chain storage (28C refrigerated)
Most patients who stop tirzepatide regain a portion of the weight they lost over time
Jeanette, 45 *Personal results may vary based on our individualized health programs
This includes coronary artery disease, heart failure, uncontrolled hypertension, arrhythmias, or history of stroke
US$ 20.96
US$ 26.07
US$ 28.82
US$ 29.23
US$ 28.61
US$ 29.32
